Search Results - "DETRE, S"

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy by Sheri, A., Smith, I.E., Johnston, S.R., A'Hern, R., Nerurkar, A., Jones, R.L., Hills, M., Detre, S., Pinder, S.E., Symmans, W.F., Dowsett, M.

“…The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the…”
Get full text

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment by Drury, S C, Detre, S, Leary, A, Salter, J, Reis-Filho, J, Barbashina, V, Marchio, C, Lopez-Knowles, E, Ghazoui, Z, Habben, K, Arbogast, S, Johnston, S, Dowsett, M

“…Development of resistance to the antioestrogen tamoxifen occurs in a large proportion of patients with oestrogen receptor-positive (ER+) breast cancer and is…”
Get full text

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer by Woolf, D K, Beresford, M, Li, S P, Dowsett, M, Sanghera, B, Wong, W L, Sonoda, L, Detre, S, Amin, V, Ah-See, M-L, Miles, D, Makris, A

“…Background: [ 18 F]fluorothymidine (FLT) has been proposed as a positron emission tomography (PET)-imaging biomarker of proliferation for breast cancer. The…”
Get full text

A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas by Detre, S, Saclani Jotti, G, Dowsett, M

“…Immunohistochemistry is increasingly used in the assessment of markers for breast cancer prognosis. Semiquantitation is frequently desirable but, other than by…”
Get full text

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience by Dowsett, M, Johnston, S, Martin, L-A, Salter, J, Hills, M, Detre, S, Gutierrez, M C, Mohsin, S K, Shou, J, Allred, D C, Schiff, R, Osborne, C K, Smith, I

“…De novo resistance to endocrine therapy is a near-universal feature of oestrogen receptor (ER)- negative breast cancer. Although many ER-positive breast…”
Get full text

Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy by ELLIS, P. A, SMITH, I. E, DETRE, S, BURTON, S. A, SALTER, J, A'HERN, R, WALSH, G, JOHNSTON, S. R. D, DOWSETT, M

“…Experimental laboratory data suggest that tumour growth is a balance between apoptosis and proliferation and that suppression of drug-induced apoptosis by…”
Get full text

Preoperative chemotherapy induces apoptosis in early breast cancer by Ellis, P A, Smith, I E, McCarthy, K, Detre, S, Salter, J, Dowsett, M

Get more information

397 Extreme loss of immunoreactive phosphoproteins during routine fixation of primary breast cancer by Pinhel, I, MacNeill, F, Hills, M, Detre, S, Salter, J, Smith, I.E, Dowsett, M

Get full text

Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay by Saccani Jotti, G, Johnston, S R, Salter, J, Detre, S, Dowsett, M

“…AIM--To validate the use of a new mouse monoclonal antibody (1D5) directed against the N-terminal domain (A/B region) of the oestrogen receptor in an…”
Get full text

Oestrogen formation in breast: clinical and biological importance by Dowsett, M, Detre, S, Rowlands, M, Grimshaw, R

“…It has been known for many years that many breast carcinomas can synthesize oestrogens from androgens via the action of the enzyme aromatase. There has been…”
Get more information

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer by Mainwaring, P N, Ellis, P A, Detre, S, Smith, I E, Dowsett, M

“…BACKGROUND: Apoptosis has a role in many cellular processes including development, normal tissue homeostasis, and malignancy. This aspect of research is…”
Get full text

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase by GUTIERREZ, M. Carolina, DETRE, Simone, JOHNSTON, Stephen, MOHSIN, Syed K, JIANG SHOU, ALLRED, D. Craig, SCHIFF, Rachel, OSBORNE, C. Kent, DOWSETT, Mitch

“…To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before…”
Get full text

The control and biological importance of intratumoural aromatase in breast cancer by Dowsett, M., Lee, K., Macaulay, V.M., Detre, S., Rowlands, M., Grimshaw, R.

“…The existence of aromatase activity in human breast carcinomas has been established for about 20 years but the clinical and biological importance of this…”
Get full text

Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival by Dowsett, Mitch, Smith, Ian E, Ebbs, Steve R, Dixon, J Michael, Skene, Anthony, Griffith, Clive, Boeddinghaus, Irene, Salter, Janine, Detre, Simone, Hills, Margaret, Ashley, Susan, Francis, Stephen, Walsh, Geraldine

“…Purpose: Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing…”
Get full text

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists by DOWSETT, Mitch, EBBS, Steve R, FRANCIS, Stephen, WALSH, Geraldine, SMITH, Ian E, DIXON, J. Michael, SKENE, Anthony, GRIFFITH, Clive, BOEDDINGHAUS, Irene, SALTER, Janine, DETRE, Simone, HILLS, Margaret, ASHLEY, Susan

“…To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy. The IMPACT trial compared the…”
Get full text

Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015) by Cheang, MCU, Morden, J, Gao, Q, Parker, J, López-Knowles, E, Detre, S, Hills, M, Zabaglo, L, Tomiczek, M, Mallon, E, Robertson, J, Smith, I, Bliss, J, Dowsett, M

“…Background Neoadjuvant endocrine therapy (NAE) is often a good option for postmenopausal (PM) women with estrogen receptor positive (ER+) breast cancers(BC)…”
Get full text

Abstract P2-05-01: Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) – Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker by Bliss, JM, Morden, J, Evans, A, Holcombe, C, Horgan, K, Mallon, E, Raghavan, V, Skene, A, Dodson, A, Hills, M, Detre, S, Zabaglo, L, Graf, M, Banerji, J, Gillman, A, Robertson, J, Dowsett, M, Smith, I

“…Background Higher levels of the proliferation marker Ki67 at breast cancer (BC) diagnosis are increasingly recognised to indicate poorer prognosis. Change in…”
Get full text

Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer by Detre, S, King, N, Salter, J, MacLennan, K, McKinna, J A, Dowsett, M

“…AIMS--(i) To assess the validity of an immunocytochemical technique for detecting pS2 protein in paraffin wax embedded tissue; (ii) to provide further data on…”
Get full text

Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance by Dowsett, M, Makris, A, Ellis, P, Johnston, S R, Salter, J, Detre, S, Humphries, S, Saccani-Jotti, G, Powles, T J, Smith, I E

Get more information

Abstract P4-01-07: Evaluation of FLT PET-CT as an imaging biomarker of proliferation in primary breast cancer by Woolf, DK, Beresford, M, Li, SP, Sanghera, B, Wong, WL, Amin, V, Ah-See, M-L, Miles, D, Sonoda, L, Detre, S, Dowsett, M, Makris, A

“…Background [18F]flurothymidine (FLT) is proposed as an positron emission tomography (PET) imaging biomarker of proliferation for breast cancer. The aim of this…”
Get full text